세계의 요로상피암 치료제 시장 : 유형별, 치료별, 최종사용자별, 지역별, 기회 및 예측(2018-2032년)

Global urothelial cancer drugs market is projected to witness a CAGR of 9.12% during the forecast period 2025-2032, growing from USD 3.03 billion in 2024 to USD 6.09 billion in 2032. The global urothelial cancer drug market is driven by the increasing prevalence of urothelial cancers, rapid adoption of immunotherapy and targeted therapies, strong R&D investments, rising awareness for early diagnosis, improved healthcare infrastructure, and favorable regulatory support, which are contributing to better treatment options and improved patient outcomes worldwide.

The global urothelial cancer drug market is expanding rapidly due to multiple advances in immunotherapy, a variety of strategic partnerships, and an increase in healthcare investment in the market. New therapies, such as combination therapy that involves immune checkpoint inhibitors, are revolutionizing the treatment of non-muscle invasive bladder cancer and improving patient outcomes and providing market opportunities across the globe.

For instance, in April 2025, European Urology Oncology published a review on immune checkpoint inhibitors for muscle-invasive bladder cancer. This highlighted rapid market growth fueled by advances in immunotherapy and evolving treatment options.

Increased Incidence Accelerates Growth in Urothelial Cancer Drug Market

Urothelial cancer incidence is on the rise and this in turn is affecting the urothelial cancer drugs market globally. As more people are diagnosed every year, many of whom are attributable to the aging population, smoking and environmental risk factors, the demand for products, either new products or improvements on existing products, is increasing rapidly. A target patient population that continues to flourish is pushing pharmaceutical companies to hasten research and development for identifying therapeutic targets and devising novel immunotherapies to address emerging clinical needs. Additionally, the healthcare system is under pressure to take on any new drug that will increase survival and quality of life for the emerging patient population.

For instance, according to the American Cancer Society, in 2025, there were projected to be 84,870 new cases of bladder cancer in the United States (about 65,080 in men and 19,790 in women) along with approximately 17,420 deaths, underscoring the growing need for effective urothelial cancer treatments.

Therapeutic and Diagnostic Advancement Fuel Urothelial Cancer Drug Market Growth

The global urothelial cancer drug market remains in growth, primarily due to improvements in treatment and discovery for urothelial cancer. Precision therapies and state-of-the-art diagnostics are evolving the entire industry landscape to improve outcomes and create a new vantage point for reasons for adoption. Targeted treatments such as FGFR inhibitors offer personalized treatments for patients identified with inherited genetic alterations to address their cancer, while immunotherapy combinations are increasingly replacing frontline therapies due to their superior outcomes relative to traditional chemotherapy. Simultaneously, novel non-invasive diagnostic tools, such as urine-based genomic assays, demonstrate unprecedented accuracy in early malignancy detection. This advancement improves treatment options and enables proactive care planning, while expanding market opportunities through earlier intervention. In sum, all these advances are expanding the population of patients that can be addressed and driving demand for advanced therapeutic agents globally.

For instance, in May 2025, the Scottish Medicines Consortium (SMC) approved BALVERSA (erdafitinib), marking a major milestone as the first licensed bladder cancer therapy to specifically target FGFR3 alterations.

Immunotherapy Leads the Global Urothelial Cancer Drug Market

Immunotherapy has become the dominant segment of the global urothelial cancer drugs market, revolutionizing treatment paradigms by harnessing the immune system to target cancer cells more effectively and with reduced toxicity compared to conventional therapies. This utilizes patient outcomes to improve where previous therapies have failed. The presence of an ever-growing pipeline of immunotherapeutic and continued regulatory approvals provides significant growth in the market and attracts significant capital as well as innovation. Immunotherapy is competitive and disruptive in ways that hospitals and medical professionals did not expect. In addition to changing treatment modalities, many treatments extend life and improve quality of life, which in turn towards personalized cancer care, or care that is specific to a patient's unique situation.

For instance, in April 2024, ImmunityBio launched ANKTIVA (nogapendekin alfa inbakicept), a first-in-class IL-15 receptor agonist, after receiving FDA approval for the treatment of BCG-unresponsive non-muscle invasive urothelial cancer.

North America Dominates the Urothelial Cancer Drugs Market Size

North America, especially the United States, is the largest geographic area for the global urothelial cancer drugs market, due to an innovative healthcare system with early adoption of new therapies and a very conducive regulatory environment for good clinical practice. In addition, the North America urothelial cancer drugs market is projected to surge owing to the existence of pharmaceutical companies, specialty oncology care is widely available, ample research funding is available, and innovators have and continue to develop treatment options, coupled with easy accessibility of advancing bladder cancer care. Regulatory authorities, such as the US Food and Drug Administration (FDA), also have a major impact on the rate of innovations, regularly using accelerated approval pathways for innovative immunotherapies and targeted drugs through various priority review designations. This expedited access to innovation in the United States market will translate to first access for clinicians to innovative therapies globally as they will enter practice sooner.

For example, in March 2024, the FDA approved nivolumab (Opdivo) in combination with cisplatin and gemcitabine for first-line treatment of adults with unresectable or metastatic urothelial carcinoma. This approval, based on the large CheckMate 901 Phase III trial, was granted priority review and introduced the first immunotherapy plus chemotherapy regimen into standard care.

Impact of U.S. Tariffs on Global Urothelial Cancer Drugs Market

Rising Manufacturing Costs: Tariffs on the APIs and finished drugs used to produce oral cancer treatments raise the manufacturing costs.

Rising Drug Prices: Patients and payers will be faced with increased costs of the treatments because of the increased manufacturing costs likely to be passed along to them.

Increased Pressure on Generic Drug Access: Generic producers operate at very limited margins and may respond by cutting back on the amount of drugs they produce or, more problematically, not producing the drugs at all, reducing access to the drugs.

Supply Chain Disruption: Import dependence means tariffs will have an impact on supply chains and possibly shortages and delays.

Time Delay on the Domestic Manufacturing Response: Building new manufacturing facilities takes multiple years, and tariffs are a short-term solution.

Restricted Patient Access: Increased prices mean that access to treatment is affected, particularly for low-income or uninsured patients.

Impact on Clinical Trial Research: Instability in drug supply can slow down or disrupt clinical research on oral medications due to difficulty accessing consistent supplies.

Key Players Landscape and Outlook

Growing the global urothelial cancer drugs market are the major pharmaceutical companies who are utilizing innovative therapies, collaborations and personalized models of treatment. The top leaders in the field are manipulating non-invasive treatment options along with immunotherapy and combination treatment options to address early treatment and resistant urothelial cancers. Companies are also responding to the unmet need of patients with non-muscle invasive bladder cancer with options that are non-invasive intravesical therapies. By forming partnerships, licensing arrangements, or co-development and agreements, these companies are expediting innovations in urothelial cancers and delivering to many regions of the world. These strategies are enhancing patient outcomes and changing current treatment options.

For example, in April 2025, Pfizer, Inc. announced that its immunotherapy drug sasanlimab, combined with BCG, significantly improved event-free survival in patients with BCG-naive, high-risk non-muscle invasive bladder cancer, demonstrating how targeted innovation by key players is driving market growth and advancing care standards.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of the U.S. Tariffs

4. Executive Summary

5. Global Urothelial Cancer Drugs Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Type
    • 5.2.1.1. Urothelial Carcinoma
    • 5.2.1.2. Squamous Cell Carcinoma
    • 5.2.1.3. Adenocarcinoma
  • 5.2.2. By Treatment
    • 5.2.2.1. Chemotherapy
    • 5.2.2.2. Immunotherapy
    • 5.2.2.3. Targeted Therapy
    • 5.2.2.4. Combination Drug Therapy
  • 5.2.3. By End-user
    • 5.2.3.1. Hospitals
    • 5.2.3.2. Cancer Treatment Centers
    • 5.2.3.3. Ambulatory Surgical Centers
    • 5.2.3.4. Others
  • 5.2.4. By Region
    • 5.2.4.1. North America
    • 5.2.4.2. Europe
    • 5.2.4.3. Asia-Pacific
    • 5.2.4.4. South America
    • 5.2.4.5. Middle East and Africa
  • 5.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Type
  • 5.3.2. By Treatment
  • 5.3.3. By End-user
  • 5.3.4. By Region

6. North America Urothelial Cancer Drugs Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Type
    • 6.2.1.1. Urothelial Carcinoma
    • 6.2.1.2. Squamous Cell Carcinoma
    • 6.2.1.3. Adenocarcinoma
  • 6.2.2. By Treatment
    • 6.2.2.1. Chemotherapy
    • 6.2.2.2. Immunotherapy
    • 6.2.2.3. Targeted Therapy
    • 6.2.2.4. Combination Drug Therapy
  • 6.2.3. By End-user
    • 6.2.3.1. Hospitals
    • 6.2.3.2. Cancer Treatment Centers
    • 6.2.3.3. Ambulatory Surgical Centers
    • 6.2.3.4. Others
  • 6.2.4. By Country Share
    • 6.2.4.1. United States
    • 6.2.4.2. Canada
    • 6.2.4.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Urothelial Cancer Drugs Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Type
        • 6.3.1.2.1.1. Urothelial Carcinoma
        • 6.3.1.2.1.2. Squamous Cell Carcinoma
        • 6.3.1.2.1.3. Adenocarcinoma
      • 6.3.1.2.2. By Treatment
        • 6.3.1.2.2.1. Chemotherapy
        • 6.3.1.2.2.2. Immunotherapy
        • 6.3.1.2.2.3. Targeted Therapy
        • 6.3.1.2.2.4. Combination Drug Therapy
      • 6.3.1.2.3. By End-user
        • 6.3.1.2.3.1. Hospitals
        • 6.3.1.2.3.2. Cancer Treatment Centers
        • 6.3.1.2.3.3. Ambulatory Surgical Centers
        • 6.3.1.2.3.4. Others
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Urothelial Cancer Drugs Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Urothelial Cancer Drugs Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Urothelial Cancer Drugs Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Urothelial Cancer Drugs Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Import Export Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

• 18.1. Regulatory Approvals
• 18.2. Clinical Trials

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

• 21.1. Competition Matrix of Top 5 Market Leaders
• 21.2. SWOT Analysis for Top 5 Players
• 21.3. Key Players Landscape for Top 10 Market Players
  • 21.3.1. Pfizer, Inc.
    • 21.3.1.1. Company Details
    • 21.3.1.2. Key Management Personnel
    • 21.3.1.3. Products and Services
    • 21.3.1.4. Financials (As Reported)
    • 21.3.1.5. Key Market Focus and Geographical Presence
    • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 21.3.2. GlaxoSmithKline plc
  • 21.3.3. Novartis AG
  • 21.3.4. F. Hoffmann La Roche Ltd.
  • 21.3.5. Astellas Pharma Inc.
  • 21.3.6. AstraZeneca plc
  • 21.3.7. Sanofi SA
  • 21.3.8. Eisai Co. Ltd.
  • 21.3.9. Merck KGaA
  • 21.3.10. UroGen Pharma, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer